Under the partnership, both firms will develop a range of digitally discovered and automatically synthesised molecules on Chemify's programmable chemistry AI platform
Dewpoint Therapeutics and Chemify to develop cancer and neurodegeneration drugs. (Credit: National Cancer Institute on Unsplash)
Biotechnology company Dewpoint Therapeutics has partnered with UK-based Chemify to accelerate the discovery of molecules targeting cancer and neurodegeneration.
Under the partnership, both firms will develop a range of digitally discovered and automatically synthesised molecules on Chemify’s programmable chemistry AI (artificial intelligence) platform.
The molecules are intended for use against specific targets of interest in US-based Dewpoint’s cancer and neurodegenerative pipelines.
The collaboration combines Dewpoint’s condensate biology and AI technology platform with Chemify’s chemistry AI and automation technology platform, which can create, find, and manufacture complex chemicals using a chemical programming language.
Chemify, which recently raised $43m in funding, has created an automated design, discovery, and synthesis platform that will be used to enhance and expedite the biotechnology firm’s ongoing chemistry activities.
Dewpoint CEO Ameet Nathwani said: “Dewpoint’s partnership with Chemify offers an innovative pathway to take our novel chemical matter already in optimization and bootstrap Chemify’s novel chemical space exploration tool suite using state-of-the-art digital chemistry AI-powered concepts.
“This is a new frontier for drug discovery and we’re delighted to partner with Chemify which is at the cutting edge of this approach.”
As part of the deal, the British firm will design and deliver a new compound and Dewpoint may decide to exercise an option to purchase the Chemify-created substances.
In return, Chemify may receive success-based tiered royalties and clinical and regulatory milestones that were previously agreed upon.
Chemify CEO Lee Cronin said: “We are extremely excited by this partnership which combines Chemify’s technology for molecular design, discovery and synthesis with Dewpoint’s condensate biology approach to produce a seamless drug discovery and design platform.
“It is truly inspiring to be using the Chemify technology I have been building for 15 years to change and improve the lives of patients.”